The decoction of licorice, ginseng, and dry ginger demonstrates anti-pulmonary fibrosis activity through modulation of the pyroptosis pathway.
文献摘要
Ethnopharmacological relevance Pulmonary fibrosis (PF) is a chronic progressive lung disease that causes damage to the lung structure and respiratory failure. Currently, there is no effective cure for this condition. The "Licorice dried ginger ginseng soup" (LGGS) recorded in Volume 3 of "Xianzheng Bingzhi" is a traditional prescription used to treat lung atrophy. However, the pharmacological mechanism of its effect on pulmonary fibrosis has not been studied yet. Aim of the study This study aims to explore the protective effects of LGGS when administered separately as silica and bleomycin in the mouse lung fibrosis model, to reveal its mechanism of action, and to focus on the NLRP3/Caspase-1/GSDMD signaling pathway. Materials and methods Two mouse models of pulmonary fibrosis were induced in C57BL/6 mice using silica and bleomycin, respectively, and LGGS was administered as intervention. Lung function, histopathology, and serum metabolites were evaluated. The major component contents in LGGS were determined by high-performance liquid chromatography (HPLC). Western blotting was performed to verify the molecular mechanism. Results LGGS significantly reduced the degree of pulmonary fibrosis in both silica- and bleomycin-induced mouse models, improved lung function, and decreased hydroxyproline (HYP) content in lung tissues. The established HPLC method effectively determined the main components with good linearity. LGGS down-regulated the protein expression of α-SMA, COL1, Caspase-1, GSDMD, and NLRP3. Conclusion LGGS exerts anti-pulmonary fibrosis effects, potentially by inhibiting the NLRP3/Caspase-1/GSDMD pyroptosis pathway. The HPLC method is accurate and reliable, providing a basis for quality control of LGGS.